The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COSTEM 2021 | Sorafenib as SOC maintenance after allo-transplant in FLT3+ AML
Andreas Burchert, MD, University of Marburg, Marburg, Germany, discusses the use of sorafenib as the new standard of care (SOC) for maintenance therapy after allogeneic transplantation for patients with FLT3+ acute myeloid leukemia (AML). Dr Burchert describes results from two randomized trials, both of which demonstrated the benefits of sorafenib after allogenic transplantation both in terms of relapse-free survival and overall survival. Dr Burchert also comments on the use of other tyrosine kinase inhibitors (TKIs) as maintenance therapy for FLT3+ AML. This interview took place at the 6th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM), which took place virtually.
